Stifel raised the firm’s price target on Disc Medicine to $73 from $71 and keeps a Buy rating on the shares. After having hosted a call with two key opinion leaders to discuss the top-line results disclosed from AURORA, the firm is increasing its view of the odds of success of bitopertin in Erythropoietic Protoporphyria to 55%, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Bitopertin Shows Promise in EPP Study
- Disc Medicine price target lowered to $50 from $80 at BMO Capital
- Disc Medicine price target lowered to $40 from $75 at Morgan Stanley
- Disc Medicine price target lowered to $71 from $104 at Stifel
- Raymond James downgrades Disc Medicine to Outperform on mixed study results
Questions or Comments about the article? Write to editor@tipranks.com